Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang, Somnath Pandey, Meghan Travers, et al.
Cell (2018) Vol. 175, Iss. 5, pp. 1244-1258.e26
Open Access | Times Cited: 202

Showing 1-25 of 202 citing articles:

Epigenetic therapy in immune-oncology
Peter A. Jones, Hitoshi Ohtani, Ankur Chakravarthy, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 3, pp. 151-161
Closed Access | Times Cited: 452
Targeting the epigenetic regulation of antitumour immunity
Simon J. Hogg, Paul A. Beavis, Mark A. Dawson, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 11, pp. 776-800
Closed Access | Times Cited: 449
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Jonathan Chou, David A. Quigley, Troy M. Robinson, et al.
Cancer Discovery (2020) Vol. 10, Iss. 3, pp. 351-370
Open Access | Times Cited: 235
CDK inhibitors in cancer therapy, an overview of recent development.
Mengna Zhang, Lingxian Zhang, Ruoxuan Hei, et al.
PubMed (2021) Vol. 11, Iss. 5, pp. 1913-1935
Closed Access | Times Cited: 225
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Justin Cidado, Scott Boiko, Theresa A. Proia, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 922-934
Open Access | Times Cited: 224
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Abdullah Al Emran, Aniruddha Chatterjee, Euan J. Rodger, et al.
Trends in Immunology (2019) Vol. 40, Iss. 4, pp. 328-344
Open Access | Times Cited: 187
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Concepción Sánchez‐Martínez, Marı́a José Lallena, Sonia Gutiérrez Sanfeliciano, et al.
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 20, pp. 126637-126637
Closed Access | Times Cited: 178
Nucleolar RNA polymerase II drives ribosome biogenesis
Karan Joshua Abraham, Negin Khosraviani, Janet N.Y. Chan, et al.
Nature (2020) Vol. 585, Iss. 7824, pp. 298-302
Open Access | Times Cited: 177
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Ping‐Chih Hsu, David M. Jablons, Cheng‐Ta Yang, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 15, pp. 3821-3821
Open Access | Times Cited: 164
CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma
Jingyue Yao, Jubo Wang, Ye Xu, et al.
Autophagy (2021) Vol. 18, Iss. 8, pp. 1879-1897
Open Access | Times Cited: 133
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis
Raymond Chen, Charles A. Ishak, Daniel D. De Carvalho
Cancer Discovery (2021) Vol. 11, Iss. 11, pp. 2707-2725
Open Access | Times Cited: 129
Endogenous retroviruses in the origins and treatment of cancer
Natasha Jansz, Geoffrey J. Faulkner
Genome biology (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 111
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
Kenneth K.W. To, Winnie Fong, William C. Cho
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 111
BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer
Beibei Liu, Xinhua Liu, Lulu Han, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 6
Open Access | Times Cited: 73
The Epigenetic Hallmarks of Cancer
Manel Esteller, Mark A. Dawson, Cigall Kadoch, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1783-1809
Closed Access | Times Cited: 17
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Changxin Wan, Matthew P. Keany, Han Dong, et al.
Cancer Research (2020) Vol. 81, Iss. 1, pp. 158-173
Open Access | Times Cited: 121
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
Aleksandra Majchrzak‐Celińska, Anna Warych, Mikołaj Szoszkiewicz
Genes (2021) Vol. 12, Iss. 2, pp. 208-208
Open Access | Times Cited: 88
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Hangzhan Ma, Nicole A. Seebacher, Francis J. Hornicek, et al.
EBioMedicine (2018) Vol. 39, pp. 182-193
Open Access | Times Cited: 85
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Tizhi Wu, Zhen Qin, Yucheng Tian, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 22, pp. 13228-13257
Closed Access | Times Cited: 78
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 64
CDK9 keeps RNA polymerase II on track
Sylvain Egloff
Cellular and Molecular Life Sciences (2021)
Open Access | Times Cited: 61
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6356-6389
Closed Access | Times Cited: 46
Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells
Zhixin Qiu, Linjie Zhao, Jia Shen, et al.
Cancer Discovery (2022) Vol. 12, Iss. 2, pp. 502-521
Open Access | Times Cited: 43
Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
Lanshu Xiao, Yi Liu, Hui Chen, et al.
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 24
Relocalizing transcriptional kinases to activate apoptosis
Roman C. Sarott, Sai Gourisankar, Basel A. Karim, et al.
Science (2024) Vol. 386, Iss. 6717
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top